Harriet Rönnholm

TL;DR: The results show that exendin‐4 is able to promote adult neurogenesis in vitro and in vivo, normalize dopamine imbalance, and increase the number of cells positive for markers of dopaminergic neurons in the substantia nigra in a model of Parkinson's disease.

TL;DR: In this paper, the authors proposed methods of promoting neurogenesis by contacting neuronal tissue with neuro-genesis modulating agents, and proposed novel methods for treating neurological disorders using neurogenescoding agents.

TL;DR: It is concluded that PACAP, through PAC1, is a potent mediator of adult neural stem cell proliferation and ex novo in vitro formation of multipotent neurospheres with the capacity to generate both neuronal and glial cells.

TL;DR: In animal models of nigrostriatal injury, a two weeks treatment with platelet-derived growth factor-BB resulted in long-lasting restoration of striatal dopamine transporter binding sites and expression of nigral tyrosine hydroxylase and is considered a clinical candidate drug for treatment of Parkinson's disease.

TL;DR: The high affinity of this ligand provides support to the hypothesis that angiotensin IV adopts a γ‐turn in the C‐terminal of its bioactive conformation.